A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer

NCT02501278 | Withdrawn Phase 2 DMC

• 2 other identifiers: EORTC-14112015-004602-42
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to assess the potential benefit of the addition of immunotherapy with VGX-3100 and INO-9012 (i.e. INO-3112) to concomitant CRT or, to concomitant CRT and continued as adjuvant in patients with locally advanced cervical cancer. Safety run-in: To test the safety of CRT combined with immunotherapy with INO-3112. This safety run-in phase will include the first 3 patients treated in each of the two INO-3112 combination arms who are exposed to at least two immunotherapy doses and evaluate whether the combination does not pose undue immediate risks to the patients further enrolled in the trial. Phase II:To demonstrate sufficient activity in the experimental combination arms to warrant a further phase III conclusive trial based on progression free survival (PFS) at 18 months assessed by RECIST by the local investigator. The efficacy will be assessed within each experimental arm while the standard arm will serve as a reference arm to check the reliability of the results.

Conditions

Uterine Cervical Neoplasms

Outcome Measures

Primary Outcomes (2)

• Occurence of Adverse Events

  In order to ensure adequate safety of the combination treatment, a safety run-in will be performed. This safety run-in phase will include the first 3 patients treated in each of the experimental arms (arms A \& B) exposed to at least two immunotherapy doses. The acute safety of the combination of INO-3112 with concomitant CRT will be evaluated similar to a phase I "3+3" safety design. The safety evaluation will be done by the Data Safety Monitoring Board who will invoke an IDMC evaluation of the whole study if undue safety signals are observed. Acute toxicity is defined as a grade 3 or more related AEs occurring between the first dose of vaccine administration and up to 14 days after the second dose of immunotherapy. Adverse events are graded according to the NCI CTCAE v4.0. Use of narcotics will be reviewed on case-to-case basis by a medical review team to assess its relevance towards the safety evaluation

  6 months

• Progression free survival (PFS) at 18 months assessed by RECIST

  Progression Free Survival at 18 months assessed by local investigator

  18 months

Study Arms (3)

Arm A: Immunotherapy during and after CRT + vaccine boost

EXPERIMENTAL

INO-3112 dosing during chemoradiotherapy plus immunotherapy dosing after chemoradiotherapy in an adjuvant setting and vaccine boost one year after last vaccine dosing.

Biological: INO-3112 vaccine; Radiation: Radiotherapy (Extrernal beam radiotherapy + brachytherapy); Drug: Cisplatin chemotherapy

Arm B: Immunotherapy during CRT + vaccine boost

EXPERIMENTAL

INO-3112 dosing during chemoradiotherapy, and vaccine boost one year after last vaccine dosing.

Biological: INO-3112 vaccine; Radiation: Radiotherapy (Extrernal beam radiotherapy + brachytherapy); Drug: Cisplatin chemotherapy

CRT without immunotherapy

ACTIVE COMPARATOR

Standard chemoradiotherapy without immunotherapy

Radiation: Radiotherapy (Extrernal beam radiotherapy + brachytherapy); Drug: Cisplatin chemotherapy

Interventions

INO-3112 vaccine BIOLOGICAL

INO-3112 i.e. the combination of VGX-3100 and INO-9012, specifically: * VGX-3100 (HPV16 and HPV18 E6-E7 DNA vaccine) will be administered at 3 mg per plasmid (6 mg total DNA) * INO-9012 (IL-12 DNA plasmid) will be administered at 1 mg per dose will be administered using the CELLECTRA® electoporation device

Arm A: Immunotherapy during and after CRT + vaccine boost; Arm B: Immunotherapy during CRT + vaccine boost

Radiotherapy (Extrernal beam radiotherapy + brachytherapy) RADIATION

The whole pelvis will be irradiated with 45 - 50.4 Gy in 25-28 fractions in fractions of 1.8 Gy over 5 weeks daily. Those patients with pelvis positive and/or para-aortic positive lymph nodes should be treated with an elective dose to the para-aortic area of 45 Gy in fractions of 1.6-1.8 Gy in 25-28 fractions. Pelvic and para-aortic nodes known to contain gross/macroscopically visible disease and heavily involved parametria or tumor areas that may lie beyond the high-dose range of brachytherapy should be treated with additional small volume boost of EBRT to a total dose of 60-65 Gy using a combination of either sequential and/or concomitant boost. Fractions of 1.8-2 Gy can be used in the sequential boost.

Arm A: Immunotherapy during and after CRT + vaccine boost; Arm B: Immunotherapy during CRT + vaccine boost; CRT without immunotherapy

Cisplatin chemotherapy DRUG

Cisplatin chemotherapy will be administered i.v. at a dose of 40 mg/m2 (total 5 cycles during week 1-5) weekly in concomitance with RT with the total dose not to exceed 70 mg per week.

Arm A: Immunotherapy during and after CRT + vaccine boost; Arm B: Immunotherapy during CRT + vaccine boost; CRT without immunotherapy

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Registration step
• Age 18 years or older;
• Newly diagnosed locally advanced cervical cancer defined as FIGO 2009: stage IB2, IIA\&IIB, IIIA\&IIIB or IVA disease;
• No evidence of distant metastases (Stage IVB);
• Histological diagnosis of squamous cell carcinoma, adenocarcinoma or adenosquamous cell carcinoma of the cervix is accepted. Not accepted are small cell, clear cell and other rare variants of the classical adenocarcinoma;
• Availability of HPV 16 and HPV 18 testing;
• No HIV seropositive, Hepatitis B or C (unless sustained virologic response achieved by anti-HCV therapy);
• Written informed consent must be given according to ICH/GCP, and national/local regulations
• Randomization step
• Positive for HPV 16 and/or HPV 18 as assessed by central lab;
• WHO/ECOG performance status 0 - 2
• Adequate hematological, liver and renal functions
• ECG with no clinically significant findings as assessed by the investigator performed within 30 days of signing the informed consent form
• Absence of current malignancies at other sites, with the exception of adequately treated basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, who have no evidence of that disease for five years and are deemed at low risk for recurrence, are eligible for the study;
• No prior history of clinically significant autoimmune disease, Crohn's disease, ulcerative colitis;

Sponsors & Collaborators

• European Organisation for Research and Treatment of Cancer - EORTC: lead
• Inovio Pharmaceuticals: collaborator
• Centre Hospitalier Universitaire Vaudois: collaborator

Study Sites (1)

Centre Hospitalier Universitaire Vaudois

Lausanne, Switzerland

Location

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Interventions

MEDI0457; Radiotherapy; Brachytherapy

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Cervical Diseases; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Intervention Hierarchy (Ancestors)

Therapeutics

Study Officials

• Fernanda Herrera

  Centre hospitalier universitaire vaudois, Lausanne

  STUDY CHAIR

• George Coukos

  Centre hospitalier universitaire vaudois, Lausanne

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 7, 2015
• First Posted: July 17, 2015
• Study Start: May 1, 2016
• Primary Completion: May 1, 2019
• Study Completion: May 1, 2021
• Last Updated: May 13, 2016

Record last verified: 2016-05

Locations

CH (1)